This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 5
  • /
  • CHMP recommends approval of Ztalmy in CDKL5 defici...

CHMP recommends approval of Ztalmy in CDKL5 deficiency disorder.- Marinus Pharma

Read time: 1 mins
Published:27th May 2023

Marinus Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Ztalmy (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.

Marinus’ application for the approval of Ztalmy in CDD is supported by data from the Phase III Marigold double-blind placebo-controlled trial, in which 101 patients were randomized and individuals treated with Ztalmy showed a median 30.7% reduction in 28-day major motor seizure frequency, compared to a median 6.9% reduction for those receiving placebo, achieving the trial’s primary endpoint (p=0.0036). In the Marigold open label extension study, patients treated with Ztalmy for at least 12 months (n=48) experienced a median 49.6% reduction in major motor seizure frequency. In the clinical development program, Ztalmy demonstrated efficacy, safety and tolerability with the most common adverse reactions (incidence of at least 5% and at least twice the rate of placebo) in the Ztalmy group being somnolence, pyrexia, salivary hypersecretion and seasonal allergy. In May 2022, the results from the Marigold study were published in The Lancet Neurology.

Condition: CDKL5 Deficiency Disorder
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.